Abstract:Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T‐DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2‐targeted therapy. Methods We conducted a phase 3, open‐label trial involving patients with HER2‐positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T‐DM1 or trastuzumab for 14 cycles. The primary end point was invasive disease–free survival (defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause). Results At the interim analysis, among 1486 randomly assigned patients (743 in the T‐DM1 group and 743 in the trastuzumab group), invasive disease or death had occurred in 91 patients in the T‐DM1 group (12.2%) and 165 patients in the trastuzumab group (22.2%). The estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T‐DM1 group and 77.0% in the trastuzumab group. Invasive disease–free survival was significantly higher in the T‐DM1 group than in the trastuzumab group (hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 0.39 to 0.64; P<0.001). Distant recurrence as the first invasive‐disease event occurred in 10.5% of patients in the T‐DM1 group and 15.9% of those in the trastuzumab group. The safety data were consistent with the known safety profile of T‐DM1, with more adverse events associated with T‐DM1 than with trastuzumab alone. Conclusions Among patients with HER2‐positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T‐DM1 than with trastuzumab alone. (Funded by F. Hoffmann–La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472.)

T-DM1 in Chinese Patients with Her2-positive Metastatic Breast Cancer: A Multi-Center, Retrospective, Real World Study.

Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study

A Phase I Study Of Pharmacokinetics Of Trastuzumab Emtansine In Chinese Patients With Locally Advanced Inoperable Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

Trastuzumab Deruxtecan (T-Dxd) Vs Trastuzumab Emtansine (T-DM1) in Patients (pts) with HER2+ Metastatic Breast Cancer (mbc): Updated Survival Results of DESTINY-Breast03.

Safety of Trastuzumab Emtansine (T-DM1) in Patients (pts) with HER2-positive Locally Advanced or Metastatic Breast Cancer (mbc): Final Results from KAMILLA Cohorts 1 (global) and 2 (Asia).

Systematic review on the safety of the new type Her-2 positive targeted drugs T-DM1 in breast cancer

A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Tyrosine Kinase Inhibitors in HER2‐positive Metastatic Breast Cancer with Trastuzumab Emtansine Resistance: Insights from a Multicenter Retrospective Real‐world Study

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

The Efficacy of Ado-trastuzumab Emtansine in HER-2 Aberrant Non-Small Cell Lung Cancer

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Supplementary Material For: Neoadjuvant Pyrotinib Plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced HER2-positive Breast Cancer in China: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Pharmacology and clinical evaluation of ado-trastuzumab emtansine for the treatment of breast cancer

Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

The Efficacy of Ado-Trastuzumab Emtansine in Patients with HER-2-aberrant Non-Small Cell Lung Cancer.

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study